Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
2.85 2.69 2.66 2.68 2.7 Last
29473 14565 8650 6800 24300 Volume
+1.06% -5.61% -1.12% +0.75% +0.75% Change
Financials ( CAD)
Sales 2017 35,1 M
EBIT 2017 -26,1 M
Net income 2017 -25,2 M
Debt 2017 -
Yield 2017 -
Sales 2018 56,4 M
EBIT 2018 -14,7 M
Net income 2018 -12,6 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 2,60x
Capi. / Sales2018 1,62x
Capitalization 91,3 M
More Financials
Company
Cardiome Pharma Corp. is a pharmaceutical company engages in provision of development and commercialization of medical products.It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.It offers the Brinavess and Aggrastat... 
Sector
Pharmaceuticals
Calendar
11/08Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
09/12 CARDIOME PHARMA : Announces Agreement with Basilea for Distribution of Zevtera®/..
09/06 CARDIOME PHARMA CORP : Cardiome, Pipeline Offers Opportunities Beyond Brinavess
09/05 CARDIOME PHARMA : to Present at the Rodman & Renshaw 19th Annual Global Investme..
08/30 CARDIOME PHARMA : New Data Presented at European Society of Cardiology Congress ..
08/11 CARDIOME PHARMA CORP : Today's Research Reports on Cardiome Pharma Corp., Microb..
08/08 CARDIOME PHARMA : Reports Second Quarter 2017 Financial Results
08/08 CARDIOME PHARMA CORP : Investor Network: Cardiome Pharma Corp. to Host Earnings ..
08/01 CARDIOME PHARMA : To Hold Second Quarter 2017 Financial Results Conference Call ..
07/05 CARDIOME PHARMA : Announces Licensing Agreement for XYDALBA™ (Dalbavancin ..
07/05 CARDIOME PHARMA : Announces Voting Results
More news
Sector news : Biopharmaceuticals
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
09/21DJPFIZER : Files Antitrust Lawsuit Against J&J -- WSJ
More sector news : Biopharmaceuticals
News from SeekingAlpha
09/04 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 4, 2017
08/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 24, 2017
08/22 HEALTHCARE GAINERS / LOSERS AS OF 11 : 10 am
08/21 Midday Gainers / Losers
08/21 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,2  CAD
Spread / Average Target 276%
EPS Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-31.82%74
BIOGEN20.55%66 607
CSL LIMITED33.20%48 262
ALEXION PHARMACEUTICALS16.81%31 898
GRIFOLS SA24.55%17 388
BIOMARIN PHARMACEUTICAL11.75%16 374